Therapeutic Effects of Endoscopic Ablation of Hunner Lesions in Interstitial Cystitis/ Bladder Pain Syndrome Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Kwang Jin Ko, Ph.D.
- Email: truelight8217@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Center, Sungkyunkwan University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female aged 18 yrs or greater
- Patients diagnosed with BPS(Bladder Pain Syndrome)
- Symptom persisted more than 6 months
- Pain VAS ≥4
- O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) scores 12 or greater with pain and nocturia domain scores > 2.
- Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF) >13
- No history of cystoscopy within 2yrs.
Exclusion Criteria:
- History of augmentation cystoplasty or previous transurethral coagulation/resection due to BPS
- Child-bearing potential, pregnant or nursing women.
- Mean voided volume lesser than 40ml or over than 400ml.
- Hematuria exceeds 1+ in the urinary dipstick (dipstick) examination.
- Urinary tract infection during run-in periods.
- Genitourinary tuberculosis or bladder,urethral and prostate cancer
- Recurrent urinary tract infection
- History of hysterectomy,mid-urethral sling,pelvic organ prolapse repair,vaginal delivery or Cesarean section,prostate operation or treatment etc within 6months.
- Neurologic disease history of cerebral infarction,multiple sclerosis or parkinsonism etc.-
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
change in recurrence-free survival time after ablation treatment
Time Frame: Every three months for one year
|
Every three months for one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
changes in mean number of daytime frequency episodes
Time Frame: Every three months for one year
|
Every three months for one year
|
|
changes in mean number of nocturia episodes
Time Frame: Every three months for one year
|
Every three months for one year
|
|
changes in mean number of urgency episodes
Time Frame: Every three months for one year
|
Every three months for one year
|
|
Change score of O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q)
Time Frame: Every three months for one year
|
Every three months for one year
|
|
Score of Global Response Assessment (GRA), Patient Global Assessment (PGA) score
Time Frame: every 3months for one year
|
every 3months for one year
|
|
Change score of Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF)
Time Frame: Every three months for one year
|
Every three months for one year
|
|
Change score of Brief Pain Inventory-short form (BPI-sf)
Time Frame: Every three months for one year
|
Every three months for one year
|
|
Occurrence of adverse event
Time Frame: Every three months for one year
|
Every three months for one year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2017-08-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Interstitial Cystitis
-
NCT02331472CompletedChronic Interstitial Cystitis
-
NCT02547298TerminatedInterstitial Cystitis
-
NCT03041194CompletedInterstitial Cystitis
-
NCT00823030Withdrawn
-
NCT00873171CompletedInterstitial Cystitis
-
NCT01997983CompletedInterstitial Cystitis | IC
-
NCT01824303Terminated
Clinical Trials on Transurethral ablation
-
NCT00890851CompletedBenign Prostatic Hyperplasia
-
NCT03814252Active, not recruiting
-
NCT02766543Active, not recruiting
-
NCT01686958Completed
-
NCT03996005CompletedLocalized Prostate Cancer | MRI Guided Transurethral Ultrasound Ablation | Ablation Therapy
-
NCT05917860Active, not recruitingProstate Cancer | Localized Prostate Carcinoma | Intermediate Risk Prostate Cancer | Castration-Naive Prostate Cancer
-
NCT07237399WithdrawnProstate Cancer (Adenocarcinoma) | Ablation Techniques | Oligometastatic Prostate Cancer (OMPC)
-
NCT03350529CompletedBenign Prostatic Hyperplasia | Locally Advanced Prostate Cancer | Locally Recurrent Prostate Cancer | Localised Prostate Cancer
-
NCT01963988Completed
-
NCT06705803Recruiting